Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Dyne Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., August 3, 2023 – Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the second quarter of 2023 and business highlights. “This is an exciting time for the entire Dyne team as we continue to enroll and dose patients in our ACHIEVE and DELIVER trials and are on track to report our first clinical data from both during the second half of this year, including evalua..."
05/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 8-K Quarterly results
Docs: "Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights - On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., May 11, 2023 – Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2023 and business highlights. “We are making excellent progress in both our ACHIEVE and DELIVER trials and are on track to report initial data from both in the second half of 2023, including evaluating the key disease-driving biomarkers of splicing in DM1 and dystrophin in DM..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights - Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD -"
11/03/2022 8-K Quarterly results
09/12/2022 8-K Other Events  Interactive Data
08/04/2022 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 -"
07/05/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
Docs: "Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-2022 -"
03/10/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
12/02/2021 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/04/2021 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights - Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne’s Co-lead Candidates into the Clinic - - Investigational New Drug Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 - WALTHAM, Mass., November 4, 2021– Dyne Therapeutics, Inc. , a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2021 and business highlights. “We made tremendous progress during the third quarter and are now preparing to advance Dyne’s two co-lead programs into the clinic, ..."
08/05/2021 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights - On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - New In Vivo Data from DM1 and DMD Programs to be Presented at Scientific Meetings this Fall -"
06/02/2021 8-K Quarterly results
05/26/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
01/19/2021 8-K Results of Operations and Financial Condition
12/09/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Lease, by and between Dyne Therapeutics, Inc. and BP3-BOS1 1560 Trapelo Road LLC",
"Lease, by and between Dyne Therapeutics, Inc. and BP3-BOS1 1560 Trapelo Road LLC"
11/05/2020 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights - Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Concept Data in Co-lead Programs, Myotonic Dystrophy Type 1 and Duchenne Muscular Dystrophy -"
09/21/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : September 21, 2020 Dyne Therapeutics, Inc. Delaware 001-39509 36-4883909 830 Winter Street Waltham, Massachusetts 02451 Registrant's telephone number, including area code: 786-8230 Not applicable",
"Restated Certificate of Incorporation of the registrant",
"Amended and Restated Bylaws of the registrant"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy